Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3′-deoxy-3′-fluorothymidine

Biochemical Pharmacology

Volumn 79, Issue 4, 2010, Pages 587-595

  Paproski, Robert J ^a   Young, James D ^a   Cass, Carol E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

3 Deoxy 3 fluorothymidine; Gemcitabine; hENT1; Nucleoside transporters; Predicting toxicity

Indexed keywords

3' FLUOROTHYMIDINE F 18; DILAZEP; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; GEMCITABINE; NITROBENZYLTHIOINOSINE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE SUBUNIT M1; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PENETRATION; DRUG SENSITIVITY; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; PANCREAS CANCER; PASSIVE TRANSPORT; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; FLUORINE RADIOISOTOPES; HUMANS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROTEIN BINDING;

EID: 71349084183     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.09.025     Document Type: Article

References (40)

1. Cartwright T., Richards D.A., and Boehm K.A. Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cancer Control 15 (2008) 308-313
2. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007) 1960-1966
3. Mackey J.R., Mani R.S., Selner M., Mowles D., Young J.D., Belt J.A., et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58 (1998) 4349-4357
4. Farrell J.J., Elsaleh H., Garcia M., Lai R., Ammar A., Regine W.F., et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136 (2009) 187-195
5. Spratlin J., Sangha R., Glubrecht D., Dabbagh L., Young J.D., Dumontet C., et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10 (2004) 6956-6961
6. Kong W., Engel K., and Wang J. Mammalian nucleoside transporters. Curr Drug Metab 5 (2004) 63-84
7. Molina-Arcas M., Trigueros-Motos L., Casado F.J., and Pastor-Anglada M. Physiological and pharmacological roles of nucleoside transporter proteins. Nucleosides Nucleotides Nucleic Acids 27 (2008) 769-778
8. Young J.D., Yao S.Y., Sun L., Cass C.E., and Baldwin S.A. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica 38 (2008) 995-1021
9. Baldwin S.A., Yao S.Y., Hyde R.J., Ng A.M., Foppolo S., Barnes K., et al. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem 280 (2005) 15880-15887
10. Barnes K., Dobrzynski H., Foppolo S., Beal P.R., Ismat F., Scullion E.R., et al. Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ Res 99 (2006) 510-519
11. Griffiths M., Beaumont N., Yao S.Y., Sundaram M., Boumah C.E., Davies A., et al. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med 3 (1997) 89-93
12. Griffiths M., Yao S.Y., Abidi F., Phillips S.E., Cass C.E., Young J.D., et al. Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem J 328 Pt 3 (1997) 739-743
13. Mackey J.R., Yao S.Y., Smith K.M., Karpinski E., Baldwin S.A., Cass C.E., et al. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 91 (1999) 1876-1881
14. Govindarajan R., Leung G.P., Zhou M., Tse C.M., Wang J., and Unadkat J.D. Facilitated mitochondrial import of anti-viral and anti-cancer nucleoside drugs by human equilibrative nucleoside transporter-3 (hENT3). Am J Physiol Gastrointest Liver Physiol (2009)
15. Ritzel M.W., Ng A.M., Yao S.Y., Graham K., Loewen S.K., Smith K.M., et al. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 276 (2001) 2914-2927
16. Ritzel M.W., Yao S.Y., Huang M.Y., Elliott J.F., Cass C.E., and Young J.D. Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1). Am J Physiol 272 (1997) C707-C714
17. Wang J., Su S.F., Dresser M.J., Schaner M.E., Washington C.B., and Giacomini K.M. Na(+)-dependent purine nucleoside transporter from human kidney: cloning and functional characterization. Am J Physiol 273 (1997) F1058-F1065
18. Hu H., Endres C.J., Chang C., Umapathy N.S., Lee E.W., Fei Y.J., et al. Electrophysiological characterization and modeling of the structure activity relationship of the human concentrative nucleoside transporter 3 (hCNT3). Mol Pharmacol 69 (2006) 1542-1553
19. Paproski R.J., Ng A.M., Yao S.Y., Graham K., Young J.D., and Cass C.E. The role of human nucleoside transporters in uptake of 3′-deoxy-3′-fluorothymidine. Mol Pharmacol 74 (2008) 1372-1380
20. Arner E.S., and Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67 (1995) 155-186
21. Been L.B., Suurmeijer A.J., Cobben D.C., Jager P.L., Hoekstra H.J., and Elsinga P.H. [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 31 (2004) 1659-1672
22. Mackey J.R., Galmarini C.M., Graham K.A., Joy A.A., Delmer A., Dabbagh L., et al. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. Blood 105 (2005) 767-774
23. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
24. Visser F., Sun L., Damaraju V., Tackaberry T., Peng Y., Robins M.J., et al. Residues 334 and 338 in transmembrane segment 8 of human equilibrative nucleoside transporter 1 are important determinants of inhibitor sensitivity, protein folding, and catalytic turnover. J Biol Chem 282 (2007) 14148-14157
25. Nakano Y., Tanno S., Koizumi K., Nishikawa T., Nakamura K., Minoguchi M., et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 96 (2007) 457-463
26. Ruiz van Haperen V.W., Veerman G., Eriksson S., Boven E., Stegmann A.P., Hermsen M., et al. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 54 (1994) 4138-4143
27. Sebastiani V., Ricci F., Rubio-Viqueira B., Kulesza P., Yeo C.J., Hidalgo M., et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 12 (2006) 2492-2497
28. Bepler G., Kusmartseva I., Sharma S., Gautam A., Cantor A., Sharma A., et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24 (2006) 4731-4737
29. Rosell R., Danenberg K.D., Alberola V., Bepler G., Sanchez J.J., Camps C., et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10 (2004) 1318-1325
30. Laing R.E., Walter M.A., Campbell D.O., Herschman H.R., Satyamurthy N., Phelps M.E., et al. Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc Natl Acad Sci U S A 106 (2009) 2847-2852
31. Clarke M.L., Damaraju V.L., Zhang J., Mowles D., Tackaberry T., Lang T., et al. The role of human nucleoside transporters in cellular uptake of 4′-thio-beta-d-arabinofuranosylcytosine and beta-d-arabinosylcytosine. Mol Pharmacol 70 (2006) 303-310
32. Pressacco J., Wiley J.S., Jamieson G.P., Erlichman C., and Hedley D.W. Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis. Br J Cancer 72 (1995) 939-942
33. Schinazi R.F., Boudinot F.D., Doshi K.J., and McClure H.M. Pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-deoxy-2′,3′-didehydrothymidine in rhesus monkeys. Antimicrob Agents Chemother 34 (1990) 1214-1219
34. Herrmann K., Eckel F., Schmidt S., Scheidhauer K., Krause B.J., Kleeff J., et al. In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors. J Nucl Med 49 (2008) 1437-1444
35. Rasey J.S., Grierson J.R., Wiens L.W., Kolb P.D., and Schwartz J.L. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43 (2002) 1210-1217
36. Schwartz J.L., Tamura Y., Jordan R., Grierson J.R., and Krohn K.A. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 44 (2003) 2027-2032
37. Huang P., and Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol 22 (1995) 19-25
38. Huang P., and Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36 (1995) 181-188
39. Veltkamp S.A., Pluim D., van Eijndhoven M.A., Bolijn M.J., Ong F.H., Govindarajan R., et al. New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine. Mol Cancer Ther 7 (2008) 2415-2425
40. Dittmann H., Dohmen B.M., Kehlbach R., Bartusek G., Pritzkow M., Sarbia M., et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 29 (2002) 1462-1469